Ask AI
ProCE Banner Activity

PURPOSE 2 Subanalysis: Annual Persistence on Twice-Yearly LEN vs Daily FTC/TDF for PrEP Among Cisgender Men and Gender-Diverse People

Conference Coverage
Slideset

Among cisgender men and gender-diverse individuals enrolled in the phase III PURPOSE 2 trial, annual persistence was significantly higher with twice-yearly subcutaneous lenacapavir PrEP versus daily oral FTC/TDF PrEP.

Released: October 22, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare